Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
Trial details
- Registry ID
- NCT07502508
- Drugs studied
- icovamenib 100 mg
TrialRedline tracks 4 clinical trials sponsored by Biomea Fusion Inc.: 3 Phase 2, 1 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based TherapyNCT07502508 | icovamenib 100 mg | Recruiting | 2027-06Estimated |
| Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic TargetsNCT07502495 | icovamenib 100mg | Active not recruiting | 2027-03Estimated |
| Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes MellitusNCT06152042 | BMF-219 | Completed | 2025-05-20Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)NCT05731544 | BMF-219 | Completed | 2024-11-18Actual |
Names as written in the registry records.
NCT06152042 · Biomea Fusion Inc.
Before: Terminated. After: Completed.
NCT07502495 · Biomea Fusion Inc.
Before: Estimated. After: Actual.
Before: 60 participants (planned). After: 64 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT07502495 · Biomea Fusion Inc.
Before: Jun 2027. After: Mar 2027.